Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Completed · Phase 1

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.

Key facts

Study ID

NCT00005057

Run by

National Human Genome Research Institute (NHGRI)

Starts

2000-03-01

Last updated by the study team

2015-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Genetherapy Branch — Bethesda, Maryland, United States
• Metabolism Branch — Bethesda, Maryland, United States
• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.